Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 24 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Jubilant Pharmova Ltd

About the Company - Jubilant Pharmova Ltd

Jubilant Pharmova Ltd. is a Public Limited Listed company incorporated on 21/06/1978 and has its registered office in the State of Uttar Pradesh, India. Company’s Corporate Identification Number(CIN) is L24116UP1978PLC004624 and registration number is 004624. Currently Company is involved in the business activities of Manufacture of basic chemicals. Company’s Total Operating Revenue is Rs. 87.75 Cr. and Equity Capital is Rs. 15.93 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsBhartiagram, Amroha District Uttar Pradesh 244223investors@jubl.com
http://www.jubilantpharmova.com
Management
NamePosition Held
Mr. Shyam S BhartiaChairman
Mr. Hari S BhartiaCo-Chairman
Mr. Priyavrat BhartiaManaging Director
Mr. Arjun Shanker BhartiaJoint Managing Director
Mr. Arvind ChokhanyWholeTime Director & Group CFO
Mr. R KumarWhole Time Director
Mr. Vivek MehraIndependent Director
Mr. Sushil Kumar RoongtaIndependent Director
Mr. Arun SethIndependent Director
Ms. Sudha PillaiIndependent Director
Dr. Ashok MisraIndependent Director
Mr. S SridharIndependent Director
Mr. Shirish G BelapureIndependent Director

Jubilant Pharmova Ltd. Share Price Update

Share PriceValue
Today₹559.40
Previous Day₹569.80

Basic Stock Data of Jubilant Pharmova Ltd

Market Cap 9,646 Cr.
Current Price 606
High / Low627/269
Stock P/E264
Book Value 340
Dividend Yield0.82 %
ROCE3.13 %
ROE6.89 %
Face Value 1.00

Data Source: screener.in

Jubilant Pharmova Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales1,7711,5801,6351,6571,3111,5281,4521,6001,5521,6781,5871,6801,677
Expenses1,2821,2051,2691,3191,1161,2801,2591,3841,4081,4591,4191,4381,459
Operating Profit490375365338194247192216144219168242218
OPM %28%24%22%20%15%16%13%14%9%13%11%14%13%
Other Income8452446-211-44102191949
Interest46433535374040425156626671
Depreciation96868810093101959494271909795
Profit before tax4312972472087010669369-862598101
Tax %28%28%35%31%28%44%32%87%285%-16%76%37%34%
Net Profit3102141601435159475-16-10066266
EPS in Rs19.4613.4310.088.973.203.742.960.34-0.98-6.150.403.924.19

Jubilant Pharmova Ltd Quarterly Chart

Jubilant Pharmova Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales4,2705,1325,7625,7515,7495,8617,5189,1115,9766,0996,1306,2826,498
Expenses3,3794,1344,7635,1414,4934,5105,9957,3674,4284,6954,9805,5035,724
Operating Profit8919999996101,2561,3521,5221,7441,5481,4031,150779773
OPM %21%19%17%11%22%23%20%19%26%23%19%12%12%
Other Income-318-93-1738641936-2492252638-958
Interest238311337368371341284220200184145188234
Depreciation221254281288347291415371340349382554552
Profit before tax114341207405427388599041,2331,1336302846
Tax %60%45%34%200%29%22%26%36%27%26%34%334%
Net Profit46189138-40387575634577898836413-65-48
EPS in Rs0.919.596.84-3.6324.6036.1440.3536.0656.3952.4725.98-3.83-2.81
Dividend Payout %328%31%43%-83%12%8%7%12%9%10%19%-130%

Jubilant Pharmova Ltd Profit & Loss Yearly Chart

Jubilant Pharmova Ltd Growth

Compounded Sales Growth
10 Years:2%
5 Years:-4%
3 Years:2%
TTM:8%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-38%
Stock Price CAGR
10 Years:19%
5 Years:-3%
3 Years:-9%
1 Year:88%
Return on Equity
10 Years:11%
5 Years:10%
3 Years:6%
Last Year:-7%

Jubilant Pharmova Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital16161516161616161616161616
Reserves2,2412,4602,6112,4382,9513,4204,0714,7935,5884,7265,3035,3835,394
Borrowings3,8184,2454,3954,7934,4934,0453,4694,8404,8082,8303,1923,6773,668
Other Liabilities1,6881,6501,8421,3721,2801,4171,9021,6701,8981,1921,3191,8532,322
Total Liabilities7,7638,3718,8648,6198,7408,8999,45711,31912,3108,7639,83010,92911,400
Fixed Assets4,4604,9675,0994,9115,1045,1075,4015,6486,3404,6094,8715,1835,989
CWIP6864374725976116846719017688971,0901,5611,095
Investments192634408510312411569241239256266
Other Assets2,5982,9413,2593,0712,9393,0063,2624,6545,1333,0173,6313,9284,050
Total Assets7,7638,3718,8648,6198,7408,8999,45711,31912,3108,7639,83010,92911,400

Jubilant Pharmova Ltd Reserves and Borrowings Chart

Jubilant Pharmova Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 7079707727831,0991,2681,3031,1221,5431,784838661
Cash from Investing Activity -596-504-164-362-309-465-614-1,018-267-727-323-474
Cash from Financing Activity -889-450-414-503-843-686-901657-1,050-1,709-33-157
Net Cash Flow-77817194-82-52117-212761225-65248230

Jubilant Pharmova Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days565051526063555179495556
Inventory Days231198200169207223177147463268308268
Days Payable19011510799106137145106273124139160
Cash Conversion Cycle971331441221621498792268194224165
Working Capital Days5040-164552665765105788677
ROCE %11%12%11%6%13%15%15%16%15%12%10%3%

Jubilant Pharmova Ltd Financial Efficiency Indicators Chart

Jubilant Pharmova Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters50.68%50.68%50.68%50.68%50.68%50.68%50.68%50.67%50.67%50.67%50.67%50.67%
FIIs25.73%25.69%24.82%23.14%23.18%23.45%23.47%23.06%23.38%23.22%23.20%23.20%
DIIs1.02%1.28%1.75%1.03%1.06%0.63%0.62%1.60%1.62%1.62%1.63%1.64%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%1.24%0.00%0.00%
Public22.57%22.29%22.68%25.09%25.01%25.18%25.17%24.59%24.20%23.11%23.91%23.89%
Others0.00%0.07%0.07%0.07%0.07%0.07%0.07%0.07%0.13%0.13%0.59%0.59%
No. of Shareholders64,84261,94287,4931,13,7761,09,4201,08,0631,09,4101,05,6321,00,21297,93593,37589,376

Jubilant Pharmova Ltd Shareholding Pattern Chart

No. of Jubilant Pharmova Ltd Shareholders

Jubilant Pharmova Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Nippon India Pharma Fund5503390.3720.61
Nippon India Nifty Smallcap 250 Index Fund462100.241.73
Motilal Oswal Nifty Smallcap 250 Index Fund290120.241.09
SBI Nifty Smallcap 250 Index Fund212920.240.8
Motilal Oswal Nifty 500 Index Fund31700.020.12
Edelweiss Nifty Smallcap 250 Index Fund9800.240.04
Motilal Oswal S&P BSE Healthcare ETF8270.380.03
Groww Nifty Total Market Index Fund1780.020.01
Motilal Oswal Nifty 500 ETF1390.020.01

Jubilant Pharmova Ltd ROCE Trend

Jubilant Pharmova Ltd EPS Trend

Jubilant Pharmova Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)-3.8326.0052.4856.3936.86
Diluted EPS (Rs.)-3.8326.0052.4856.3936.86
Cash EPS (Rs.)29.9850.5573.7077.7259.51
Book Value[Excl.RevalReserv]/Share (Rs.)338.91333.97297.85351.78301.90
Book Value[Incl.RevalReserv]/Share (Rs.)338.91333.97297.85351.78301.90
Revenue From Operations / Share (Rs.)394.85385.08383.10375.13571.96
PBDIT / Share (Rs.)51.2073.3588.8399.52111.42
PBIT / Share (Rs.)16.3849.3766.9178.1988.13
PBT / Share (Rs.)0.9740.2354.0163.5856.74
Net Profit / Share (Rs.)-4.8526.5751.7856.3936.22
NP After MI And SOA / Share (Rs.)-3.8326.0052.5156.3936.06
PBDIT Margin (%)12.9619.0423.1826.5219.47
PBIT Margin (%)4.1412.8217.4620.8415.40
PBT Margin (%)0.2410.4414.0916.949.92
Net Profit Margin (%)-1.226.9013.5115.036.33
NP After MI And SOA Margin (%)-0.976.7513.7015.036.30
Return on Networth / Equity (%)-1.127.7817.6216.0211.94
Return on Capital Employeed (%)2.779.3513.5312.5714.96
Return On Assets (%)-0.544.149.377.175.00
Long Term Debt / Equity (X)0.570.460.540.660.88
Total Debt / Equity (X)0.630.550.540.780.98
Asset Turnover Ratio (%)0.120.010.370.370.47
Current Ratio (X)2.122.202.811.922.19
Quick Ratio (X)1.341.421.741.221.52
Inventory Turnover Ratio (X)0.500.001.441.621.99
Dividend Payout Ratio (NP) (%)-130.6019.230.0016.848.31
Dividend Payout Ratio (CP) (%)16.1510.000.0012.225.05
Earning Retention Ratio (%)230.6080.770.0083.1691.69
Cash Earning Retention Ratio (%)83.8590.000.0087.7894.95
Interest Coverage Ratio (X)4.338.037.687.948.07
Interest Coverage Ratio (Post Tax) (X)0.893.914.174.564.90
Enterprise Value (Cr.)6827.698114.6012743.976953.8913952.33
EV / Net Operating Revenue (X)1.091.322.091.161.53
EV / EBITDA (X)8.386.959.014.397.86
MarketCap / Net Operating Revenue (X)0.701.011.780.661.16
Retention Ratios (%)230.6080.760.0083.1591.68
Price / BV (X)0.821.162.280.702.20
Price / Net Operating Revenue (X)0.701.011.780.661.16
EarningsYield-0.010.060.070.220.05

Jubilant Pharmova Ltd Profitability Ratios (%)

Jubilant Pharmova Ltd Liquidity Ratios

Jubilant Pharmova Ltd Liquidity Ratios (%)

Jubilant Pharmova Ltd Interest Coverage Ratios (%)

Jubilant Pharmova Ltd Valuation Ratios

Fair Value of Jubilant Pharmova Ltd Stock

Fair Value: ₹6235.18

The stock is undervalued by 928.91% compared to the current price ₹606

*Investments are subject to market risks

Strength and Weakness of Jubilant Pharmova Ltd Stock

StrengthWeakness
  1. The company has shown consistent growth in sales (5.69 cr) and profit (342.38 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 59.80 and average Dividend Yield of 14.13%.
  2. The stock has a low average ROCE of 11.58%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 58.75, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 153.08, which may not be favorable.
  5. The company has higher borrowings (4,021.00) compared to reserves (3,952.23), which may suggest financial risk.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Jubilant Pharmova Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE